...
首页> 外文期刊>Bulletin of experimental biology and medicine >Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms.
【24h】

Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms.

机译:黑色素瘤和良性皮肤色素瘤中的组织和尿激酶型纤溶酶原激活物和1型纤溶酶原激活物抑制剂。

获取原文
获取原文并翻译 | 示例

摘要

The content of urokinase- and tissue-type plasminogen activators and plasminogen activator inhibitor PAI-1 in the cytosol of primary and metastatic melanomas and benign skin pigment neoplasms was estimated by enzyme immunoassay. It was shown that local growth and invasion of melanomas are related to suppressed expression of tissue plasminogen activator. The content of urokinase plasminogen activator increases in patients with distant metastases and large thickness of the primary tumor.
机译:通过酶免疫法评估原发性和转移性黑素瘤和良性皮肤色素瘤细胞质中尿激酶和组织型纤溶酶原激活物和纤溶酶原激活物抑制剂PAI-1的含量。结果表明,黑色素瘤的局部生长和侵袭与组织纤溶酶原激活物的表达受抑制有关。转移远,原发灶厚的患者尿激酶纤溶酶原激活剂的含量会增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号